Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [906]
News [2550]
Articles [106]
Editorials [3]
Conferences [84]
elearning [20]
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse...
Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction ( Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA )
29 May 2015
Genomic marker predicts anti-PD-1 response in several cancers
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Genomic marker predicts anti-PD-1 response in several cancers ( Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
29 May 2015
Nivolumab extends survival for NSCLC
Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Nivolumab extends survival for NSCLC ( Prof Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
29 May 2015
Nivolumab extends survival for patients with the most common lung cancer
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
Nivolumab extends survival for patients with the most common lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
29 May 2015
Genomic marker predicts anti-PD-1 response in several cancers
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Genomic marker predicts anti-PD-1 response in several cancers ( Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
29 May 2015
'Liquid biopsy' may help earlier detection of lung cancer treatment resistance
Dr Jonas Nilsson - Umeå University, Umeå, Sweden
'Liquid biopsy' may help earlier detection of lung cancer treatment resistance ( Dr Jonas Nilsson - Umeå University, Umeå, Sweden )
13 May 2015
Pembrolizumab found to be safe with durable responses in advanced non-small...
Dr Edward Garon - David Geffen School of Medicine at the University of...
Pembrolizumab found to be safe with durable responses in advanced non-small cell lung cancer ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )
1 May 2015
How is ganetespib regulating the response of tumour cells in lung cancer?
Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA
How is ganetespib regulating the response of tumour cells in lung cancer? ( Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA )
30 Apr 2015
How will genomics be applied to patient therapy in future?
Dr Jean Claude Zenklusen - Director, The Cancer Genome Atlas
How will genomics be applied to patient therapy in future? ( Dr Jean Claude Zenklusen - Director, The Cancer Genome Atlas )
30 Apr 2015
Pembrolizumab showed clinical benefit in malignant pleural mesothelioma
Dr Evan Alley - University of Pennsylvania, Philadelphia, USA
Pembrolizumab showed clinical benefit in malignant pleural mesothelioma ( Dr Evan Alley - University of Pennsylvania, Philadelphia, USA )
29 Apr 2015
Pembrolizumab promising for lung cancer, clinical outcomes correlate with...
Dr Edward Garon - David Geffen School of Medicine at the University of...
Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )
27 Apr 2015
New approaches and new partnership models for biomarker based clinical research
Dr Denis Lacombe, EORTC, Brussels, Belgium
New approaches and new partnership models for biomarker based clinical research ( Dr Denis Lacombe, EORTC, Brussels, Belgium )
6 Jan 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation